DT&C Bio Group Participates in 'KoNECT International Conference'

[Financial News] DT&C Bio Group announced on the 8th that it will participate in the '2025 KoNECT MOHW MFDS International Conference (KoNECT International Conference)' held at Lotte Hotel Seoul from the 22nd to the 24th, showcasing integrated capabilities from non-clinical to regulatory.
This event is a representative event in the biopharmaceutical field jointly hosted by the Ministry of Health and Welfare and the Ministry of Food and Drug Safety, serving as a platform for discussing the innovation ecosystem across the entire cycle of clinical trials, new drug development, and regulatory science.
During the event, DT&C Bio Group will operate booths 30 and 31 on the 3rd floor of Lotte Hotel's exhibition hall, with participation from group affiliates such as △DT&CRO △HuScience △SafeSoft. Through this event, DT&C Bio Group plans to introduce group integrated services such as △non-clinical and clinical trials △bioanalysis △AI-based safety evaluation solutions, while seeking opportunities to collaborate with domestic and international companies and institutions.
In particular, DT&C Bio Group and DT&CRO support the overseas expansion of domestic biotech, comprehensively assisting with not only the Ministry of Food and Drug Safety but also the US FDA, European EMA approvals, and global clinical trials. This helps domestic companies overcome regulatory barriers and demonstrate new drug development capabilities in the global market.
A representative of DT&C Bio Group said, "This event is an important opportunity to interact with global pharmaceutical and biotech companies, researchers, and regulatory agencies," adding, "Through this participation, we will contribute to the development of the domestic bio ecosystem and the expansion of global cooperation."
Meanwhile, DT&C Bio Group has affiliates such as DT&CRO, a 'GLP' certified testing institution, HuScience, which operates a biopharmaceutical analysis platform, and SafeSoft, an AI-based toxicity prediction software company. It is strengthening its role as a bridge connecting domestic biotech and the global market based on a one-stop support system encompassing research and development, clinical, and regulatory response.

butter@fnnews.com Kang Kyung-rae Reporter